# US 2013/0157953 A1 · Treatment of cardiac conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157953 A1
- Document ID: US20130157953A1
- Status: Published application
- Kind: A1
- Application number: 13/574,197
- Filed: 2011-01-20
- Published: 2013-06-20
- Earliest claimed: 2010-01-20
- Assignees: Zealand Pharma A/S
- Inventors: Jørgen Søberg Petersen; Anne Louise Kjoelbye; Marie Skovgaard; Henrik Duelund Pedersen; Lene Axelsen; Ditte Riber; Eddi Meier; Rie Schultz Hansen; Keld Fosgerau; Bjarne Due Larsen
- Web page: https://patentgrep.com/patent/US20130157953A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/26: Glucagons
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.

## Claims

### Claim 1

A method of treating heart disease or heart dysfunction in a subject, comprising administering a glucagon-GLP-1 dual agonist to the subject as a positive inotropic agent.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said heart disease or heart dysfunction is selected from the group consisting of: congestive heart failure, systolic dysfunction, diastolic dysfunction, myocardial infarction, ischemic heart disease, diabetic cardiomyopathy and combinations thereof.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist is administered in combination with an agent for treatment of a condition selected from heart failure, diabetes, obesity, myocardial infarction, hypolipidemia and hypertension.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist is a compound having the formula:
R1—X—Z1—Z2—R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
X has the Formula I:
SEQ ID NO: 105
X1-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-Tyr-Leu-X15-X16-
X17-X18-Ala-X20-X21-Phe-X23-X24-Trp-Leu-X27-X28-X29
wherein
X1 is His, D-His, (Des-amino)His, hydroxyl-His, acetyl-His, homo-His, alpha,alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl His, alpha-methyl His or imidazole acetic acid;
X2 is Ser, Aib or D-Ser;
X3 is Gln, Glu, Orn or Nle;
X10 is Tyr or Trp;
X12 is Lys, Arg, His, Ala, Leu, Dpu, Dpr, Orn, Citrulline or Ornithine;
X15 is Asp, Glu, cysteic acid, homoglutamic acid or homocysteic acid;
X16 is Ser, Thr, Lys, Arg, His, Glu, Asp, Ala, Gly, Gln, homoglutamic acid or homocysteic acid;
X17 is Arg, Lys, His, Glu, Gln, Ala, Leu, Dpu, Dpr, Orn, Cys, homocysteine or acetyl phenylalanine;
X18 is Arg, Lys, His, Tyr, Ala, Ser, Leu, Cys, Orn, homocysteine or acetyl phenylalanine;
X20 is Gln, Lys, Arg, His, Glu, Asp, Ala, Cys, Orn or Citrulline;
X21 is Asp, Glu, Gln, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
X23 is Val, Ile or Leu;
X24 is Gln, Lys, Arg, Glu, Asp, Ser, Ala, Leu, Cys, Orn, homocysteine or acetyl phenyalanine;
X27 is Met, Lys, Arg, Glu, Leu, Nle, Cys or absent;
X28 is Asn, Lys, Arg, Glu, Asp, Ser, Ala, Leu, Cys, Citrulline, Orn, or absent;
X29 is Thr, Lys, Arg, Glu, Ser, Ala, Gly, Cys, Orn, homocysteine, acetyl phenyalanine or absent;
R2 is NH2 or OH;
Z1 is absent or has the sequence:
Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser;
Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser Cys;
Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala;
or
Lys Arg Asn Arg;
Z2 is absent or a peptide sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
wherein, if Z1 is present, X27, X28 and X29 are also present; and
if Z1 is absent, the compound has a substitution or deletion relative to human glucagon at one or more of positions X1, X2, X3, X10, X12, X15, X16, X17, X18, X20, X21, X23, X24, X27, X28 and X29;
or a pharmaceutically acceptable salt or derivative thereof;
wherein said compound has higher GLP-1 receptor selectivity than human glucagon.

### Claim at position 6

7-29. (canceled)

### Claim 30 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist has the formula R1—X—Z2—R2
wherein
R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R2 is OH or NH2;
X is a peptide which has the Formula III:
SEQ ID NO: 13
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Leu-Tyr-Leu-Asp-
Ser-Arg-Arg-Ala-Lys-Asp-Phe-Ile-Glu-Trp-Leu-Glu-Ser-Ala
or differs from Formula III at up to 4 of the following positions whereby, if different from Formula III:
the residue at position 2 is selected from: Aib, D-Ser;
the residue at position 16 is selected from: Arg, His, Lys, Glu, Gly, Asp;
the residue at position 17 is selected from: Lys, Leu;
the residue at position 18 is selected from Lys, His, Ala, Ser, Tyr;
the residue at position 20 is selected from: Gln, His, Arg, Glu, Asp;
the residue at position 21 is: Glu;
the residue at position 23 is selected from: Val, Leu;
the residue at position 24 is selected from: Gln, Leu, Ala, Lys, Arg, Asp;
the residue at position 27 is selected from Met, Cys, Lys, Arg, Leu or is absent
the residue at position 28 is selected from Asn, Arg, Lys, Glu, Ala, Leu, Asp or'is absent and
the residue at position 29 is selected from Thr, Glu, Lys or is absent
and Z2 is absent or a peptide sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
or a pharmaceutically acceptable salt thereof.

### Claim at position 8

31-40. (canceled)

### Claim 41 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist has the formula R1—X—Z2—R2
wherein
R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R2 is OH or NH2;
X is a peptide which has the Formula V:
SEQ ID NO: 36
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Lys-Ala-Ala-His-Asp-Phe-Val-Glu-Trp-
Leu-Leu-Arg-Ala
or differs from Formula V at up to 4 of the following positions whereby, if different from Formula V:
the residue at position 2 is selected from: Aib, D-Ser;
the residue at position 12 is selected from: Leu, Arg, Dpu, Dpr, Orn;
the residue at position 16 is selected from: Arg, His, Lys, Glu, Asp;
the residue at position 17 is selected from: Arg, Leu, Dpu, Dpr, Orn;
the residue at position 18 is selected from: Arg, Lys, His, Ser, Tyr;
the residue at position 20 is selected from: Gln, Lys, Arg, Glu, Asp;
the residue at position 21 is Glu;
the residue at position 24 is selected from: Gln, Leu, Ala, Lys, Arg, Asp;
the residue at position 27 is selected from: Met, Cys, Lys, Arg, Glu or is absent;
the residue at position 28 is selected from: Asn, Ser, Lys, Glu, Ala, Leu, Asp or is absent; and
the residue at position 29 is selected from: Thr, Glu, Lys or is absent;
and Z2 is absent or a peptide sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
or a pharmaceutically acceptable salt thereof.

### Claim at position 10

42-45. (canceled)

### Claim 46 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist has the formula R1—X—Z2—R2
wherein
R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R2 is OH or NH2;
X is a peptide which has the Formula VI:
SEQ ID NO: 49
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-
Ser-Lys-Ala-Ala-His-Asp-Phe-Val-Glu-Trp-Leu-Leu-Arg-Ala
or differs from Formula VI at up to 5 of the following positions whereby, if different from Formula VI:
the residue at position 2 is selected from: Aib, D-Ser;
the residue at position 16 is selected from: Arg, His, Lys, Glu;
the residue at position 17 is: Arg, Leu, Dpu, Dpr, Orn;
the residue at position 20 is selected from: Gln, Lys, Arg, Glu, Asp;
the residue at position 21 is Glu;
the residue at position 24 is selected from: Gln, Leu, Ala, Lys, Arg, Asp;
the residue at position 27 is selected from: Met, Cys, Lys, Arg, Glu or is absent;
the residue at position 28 is selected from: Asn, Ser, Lys, Glu, Ala, Leu, Asp or is absent; and
the residue at position 29 is selected from: Thr, Glu, Lys or is absent;
and Z2 is absent or a peptide sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
or a pharmaceutically acceptable salt thereof.

### Claim at position 12

47-53. (canceled)

### Claim 54 (depends on 1)

The method according to claim 1, wherein the glucagon-GLP-1 dual agonist has the formula R1—X—Z1—Z2—R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
wherein X has the Formula VII:
SEQ ID NO: 343
X1-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-Tyr-Leu-X15-X16-
X17-X18-Ala-X20-X21-Phe-X23-X24-Trp-Leu-X27-X28-X29
wherein
X1 is His, D-His, (Des-amino)His, hydroxyl-His, acetyl-His, homo-His, alpha,alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl His, alpha-methyl His, or imidazole acetic acid;
X2 is Ser, D-Ser, Ala, D-Ala, Val, Gly, N-methyl Ser, aminoisobutyric acid (Aib) or N-methyl Ala;
X3 is Gln, Glu, Orn or Nle;
X10 is Tyr or Trp;
X12 is Lys, Citrulline, Orn or Arg;
X15 is Asp, Glu, cysteic acid, homoglutamic acid or homocysteic acid;
X16 is Ser, Glu, Gln, homoglutamic acid or homocysteic acid;
X17 is Arg, Gln, Lys, Cys, Orn, homocysteine or acetyl phenylalanine;
X18 is Arg, Ala, Lys, Cys, Orn, homocysteine or acetyl phenylalanine;
X20 is Gln, Lys, Arg, Orn or Citrulline;
X21 is Gln, Glu, Asp, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
X23 is Val or Ile;
X24 is Ala, Gln, Glu, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
X27 is Met, Leu or Nle;
X28 is Asn, Arg, Citrulline, Orn, Lys or Asp;
X29 is Thr, Gly, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
R2 is NH2 or OH;
Z1 is absent or has the sequence:
Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser;
Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser Cys;
Lys-Arg-Asn-Arg-Asn-Asn-lle-Ala;
or
Lys Arg Asn Arg;
Z2 is absent or a peptide sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Har, Dbu, Dpr and Orn;
wherein, if Z1 is absent, the compound has a substitution or deletion relative to human glucagon at one or more of positions X1, X2, X3, X10, X12, X15, X16, X17, X18, X20, X21, X23, X24, X27, X28 and X29;
or a pharmaceutically acceptable salt or derivative thereof;
wherein said compound has higher GLP-1 receptor selectivity than human glucagon and/or wherein the compound exhibits at least 20% of the activity of native GLP-1 at the GLP-1 receptor.

### Claim 55 (depends on 54)

The method according to claim 54, wherein X differs from Formula VII by 1 to 3 amino acid modifications at positions selected from 1, 2, 3, 5, 7, 10, 11, 13, 14, 17, 18, 19, 21, 24, 27, 28 and 29.

### Claim at position 15

56-118. (canceled)

### Claim 119 (depends on 6)

The method according to claim 6, wherein Z2 is absent.

### Claim 120 (depends on 6)

The method according to claim 6, wherein Z1 is absent.

### Claim at position 18

121-122. (canceled)

### Claim 123 (depends on 6)

The method according to claim 6, wherein one or more of the amino acid side chains of the glucagon-GLP-1 agonist is conjugated to a lipophilic substituent.

### Claim at position 20

124-133. (canceled)

### Claim 134 (depends on 123)

The method according to claim 123, wherein each lipophilic substituent comprises a lipophilic moiety conjugated to the amino acid side chain by a spacer.

### Claim 135 (depends on 134)

A method according to claim 134 wherein the combination of lipophilic moiety and spacer is selected from dodecanoyl-γ-Glu, hexadecanoyl-γ-Glu, hexadecanoyl-Glu, hexadecanoyl-[3-aminopropanoyl], hexadecanoyl-[8-aminooctanoyl], hexadecanoyl-ε-Lys, 2-butyloctanoyl-γ-Glu, octadecanoyl-γ-Glu and hexadecanoyl-[4-aminobutanoyl].

### Claim at position 23

136-154. (canceled)
